• Explore /
  • Poster
  • / Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.

Ipilimumab/nivolumab (I/N) compared to axitinib/pembrolizumab (A/P) in metastatic renal cell carcinoma (mRCC): Insights from a Canadian population.

Abstract Poster

Authors

null

Hyejee Ohm

Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

Hyejee Ohm , Sunita Ghosh , Mehul Gupta , Lori Wood , Vincent Castonguay , Jeffrey Graham , Christian K. Kollmannsberger , Dominick Bosse , Denis Soulieres , Daniel Yick Chin Heng , Nazanin Fallah-Rad , Antonio Finelli , Simon Tanguay , Aly-Khan A. Lalani , Bimal Bhindi , Georg A. Bjarnason , Rodney H. Breau , Frederic Pouliot , Naveen S. Basappa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer; Adrenal, Penile, and Testicular Cancers

Track

Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer

Sub Track

Quality of Care/Quality Improvement and Real-World Evidence

Citation

J Clin Oncol 42, 2024 (suppl 4; abstr 393)

DOI

10.1200/JCO.2024.42.4_suppl.393

Abstract #

393

Poster Bd #

F17

Abstract Disclosures

Similar Posters

First Author: Joseph Vento

First Author: Aitzaz Qaisar

First Author: Neil J. Shah

First Author: Chun Loo Gan